跳至主要内容
临床试验/NCT01342718
NCT01342718已完成不适用

Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea

Kyunghee University Medical Center2 个研究点 分布在 2 个国家目标入组 48 人开始时间: 2011年4月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
48
试验地点
2
主要终点
Adequate relief (AR) of IBS pain & discomfort

研究概览

简要总结

The aims of this study are to investigate the effect of famous herbal formula extract and probiotics on irritable bowel syndrome with diarrhea, and to determine whether these two experimental items affect intestinal permeability and the composition of intestinal microbiota.

详细描述

Irritable bowel syndrome (IBS), a common chronic gastrointestinal disorder characterized by abdominal pain and alteration of bowel habits in the absence of structural abnormality, has a prevalence of approximately 15% in western populations1,2. Patients with IBS can be classified by their predominant bowel habits: diarrhea-predominant IBS (D-IBS), constipation-predominant IBS, or IBS with alternating bowel movements3. Although smooth-muscle relaxants, bulking agents, and anti-diarrheal agents are commonly used as conventional IBS treatments, many IBS patients turn to alternative treatments because of the lack of therapeutic advantages of these treatments4. Therefore, the development of a new therapy is necessary for IBS patients.

Gwakhyangjeonggisan (GJS; Kkako-shoki-san in Kampo Medicine; Huoxiang-zhengqi-san in Traditional Chinese Medicine), which was recorded originally in the famous ancient herbal formula literature "Formularies of the Bureau of people's Welfare Pharmacies", consists of 13 common crude herbs. GJS contains the chemical ingredients naringin, hesperidin, thymol, honokiol and magnolol5. GJS has been shown to protect intestinal barrier function6, contract the colonic muscle7, and regulate infectious diarrhea8 in vivo. In traditional Korean medicine, this herbal formula has long been used for relieving abdominal pain, diarrhea, and vomiting as an over-the-counter or prescribed medicine9-11. However, there have been no clinical trials to investigate the efficacy of GJS in IBS.

Probiotics are defined as viable microorganisms, which confer potential health benefits on the host when taken in proper amounts12. They are easily available, do not require a prescription, and are administered extensively for the relief of abdominal symptoms13. According to a recent systematic review and meta-analysis study, probiotics caused a modest improvement in the overall IBS symptoms14. The rationale for using probiotics for IBS is based on the assumption that they modify the composition of the intestinal microflora15 and regulate intestinal permeability by modulating the epithelial tight junctions16. Duolac7S (DUO), a probiotic mixture, contains 7 bacterial species including Bifidobacterium, Lactobacillus, and Streptococcus. Each of these bacterial species is reportedly beneficial for IBS17. DUO has been approved by the Korean Food and Drug Administration for restoring the ecological balance of intestinal microflora and improving intestinal symptoms18. Although DUO has been widely used as an over-the-counter product for IBS-related symptoms, no clinical trials have investigated the efficacy of DUO on IBS.

Recently, several herbal formulas and probiotics have been simultaneously administered to IBS patients for relieving abdominal symptoms19. In addition to lack of clinical evidence for the use of GJS or DUO, the efficacy of their combined treatment for IBS has not been elucidated. Thus, there is a need to evaluate the safety and efficacy of administration of GJS, DUO, or a combination therapy as a frequently used treatment for IBS. In the current trial, we identified the safety and efficacy of GJS, DUO, or a combination therapy on D-IBS by evaluating IBS symptoms and quality of life. To investigate their mechanisms in humans, intestinal permeability and composition of intestinal microbiota were assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age of 18 - 75, with a elementary-school diploma or higher, must be literate
  • One who meet Rome Ⅲ IBS-D criteria
  • One who agree on not taking other therapies during experimental period
  • During the past 5 yrs, no history of organic lesion proven by colonoscopy
  • One who agree on consent form

排除标准

  • Patients who have abdominal operation in the past(exception: appendectomy, caesarean section, tubal ligation, laparoscopic cholecystectomy, hysterectomy and abdominal wall hernia repair)
  • No history of non-functional bowel disease(cholangitis, pancreatitis, enteritis, ulcer, bleeding, cancer, etc.)
  • Before participation clinical trial, one who took over-the-count medication affecting GI motility
  • One who takes antibiotics during run-in period (2 wks)
  • One who takes probiotics within 2 wks before experiment
  • Pregnant woman
  • One who disagree on the consent form

研究组 & 干预措施

GJS-P/Duolac7S

Placebo Comparator

GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics

干预措施: Placebo herbal extract granule and probiotics (Dietary Supplement)

GJS/Duolac7S-P

Placebo Comparator

GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics

干预措施: Herbal extract granule and placebo probiotics (Dietary Supplement)

GJS-P/Duolac7S-P

Placebo Comparator

GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics

干预措施: Placebo herbal extract granule and placebo probiotics (Dietary Supplement)

GJS/Duolac7S

Experimental

GJS: Real herbal extract granule/Duolac7S: Real probiotics

干预措施: Herbal extract granule and probiotics (Dietary Supplement)

结局指标

主要结局

Adequate relief (AR) of IBS pain & discomfort

时间窗: Weekly (during run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])

As the participants answer the question "in the past seven days have you had adequate relief of your irritable bowel syndrome pain and discomfort?" in the form of "Yes" or "No", the effect can be assessed.

Proportion of responders

时间窗: Once in each period (run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks])

The proportion of responders who answer "Yes" to more than half of AR questions in each period (\>50%)

次要结局

  • Daily assessment of bowel function scores(Daily (during run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks]))
  • Daily assessment of severity of individual symptoms related to defecation(Daily (during run-period [2 wks], administarion period [8 wks] and follow-up period [2 wks]))
  • Changes on population of intestinal microbes(Two times in administration period (0 and 8 wks))
  • Intestinal permeability test(Two times in administration period (0 and 8 wks))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Seok-Jae Ko

Resident, Department of Internal Medicine

Kyunghee University Medical Center

研究点 (2)

Loading locations...

相似试验